Nathan P. Lawrence
Keine laufenden Positionen mehr
Vermögen: 46 $ am 31.05.2024
Karriereverlauf von Nathan P. Lawrence
Ehemalige bekannte Positionen von Nathan P. Lawrence
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Boston Biomedical, Inc.
 Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
| PRESSURE BIOSCIENCES, INC. | Vertrieb & Marketing | 01.08.2005 | - |
Ausbildung von Nathan P. Lawrence
| University of Miami | Undergraduate Degree |
| Southern Connecticut State University | Graduate Degree |
| Yale University | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Sales & Marketing | 1 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sektoral
| Consumer Services | 4 |
| Health Technology | 2 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PRESSURE BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Boston Biomedical, Inc.
Boston Biomedical, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sumitomo Chemical Co., Ltd., Boston Biomedical, Inc. is a developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company is based in Norwood, MA. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. The company was founded by Chiang J. Li. Boston Biomedical was acquired by Sumitomo Pharma Co., Ltd. on April 25, 2012 for $2,630 million. | Commercial Services |
- Börse
- Insiders
- Nathan P. Lawrence
- Erfahrung